Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors

Iovance Biotherapeutics Appoints Athena

Countouriotis, M.D., to Board of Directors

SAN CARLOS, Calif., June 11, 2019 -- Iovance

Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating

lymphocyte (TIL) technology, today announced the appointment of Athena Countouriotis, M.D., to the company's Board of Directors,

effective June 10, 2019. Dr. Countouriotis is the President and Chief Executive Officer of Turning Point Therapeutics and specialized

in hematology and oncology in her professional career.

"Dr. Countouriotis has a long record of successful leadership

in oncology drug development, and particular expertise in bringing novel therapies through clinical development," commented

Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. "We are delighted to expand our Board

with new members with deep drug development experience."

"I am excited to join the board at such an important time

for the company following the strong data shown at ASCO with LN-145 in cervical cancer and with lifileucel in advanced melanoma,"

said Dr. Countouriotis. "Both therapies have such great potential to benefit patients and I look forward to working with

the company and the board to make these therapies available to patients."

Dr. Countouriotis previously served as Chief Medical Officer

for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier

in her career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent, Mylotarg, Bosulif

and Sprycel. She currently serves on the board of directors at Turning Point Therapeutics and Trovagene. Dr. Countouriotis holds

an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine.

She received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric

Hematology-Oncology Program.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics intends to commercialize autologous

cell therapy products that amplify the body's own immune response to eradicate solid tumors or attack blood cancers. The

company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma. In addition, the company's

tumor infiltrating lymphocyte (TIL) therapies are being investigated for the treatment of patients with locally advanced, recurrent

or metastatic cancers including cervical, head and neck, and non-small cell lung cancer. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking

statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us,"

or "our"). We may, in some cases, use terms such as "predicts," "believes," "potential,"

"continue," "estimates," "anticipates," "expects," "plans," "intends,"

"may," "could," "might," "will," "should" or other words that convey

uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include,

but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, manufacturing and production

capabilities, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates (including

both Company-sponsored and collaborator-sponsored trials in both the U.S. and Europe), such as statements regarding the timing

of initiation and completion of these trials; the timing of and our ability to obtain and maintain FDA or other regulatory authority

approval of, or other action with respect to, our product candidates, including those product candidates that have been granted

breakthrough therapy designation ("BTD") or regenerative medicine advanced therapy designation ("RMAT")

by the FDA; the strength of the Company's product pipeline; the successful implementation of the Company's research

and development programs and collaborations; the Company's ability to obtain tax incentives and credits; the success of

the Company's manufacturing, license or development agreements; the acceptance by the market of the Company's product

candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the

Company's control. The factors discussed herein could cause actual results and developments to be materially different from

those expressed in or implied by such statements. Actual results may differ from those set forth in this press release due to

the risks and uncertainties inherent in the Company's business, including, without limitation; the preliminary clinical

results, including efficacy and safety results, from ongoing Phase 2 studies may not be reflected in the final analyses of these

trials, including new cohorts within these trials, and may not be supportive of product approval; the FDA or other regulatory

authorities may potentially delay the timing of their approval of, or other action with respect to, the Company's product

candidates; the Company's ability to address FDA or other regulatory authority requirements relating to its clinical programs

and registrational plans, such requirements including, but not limited to, clinical and safety requirements as well as manufacturing

and control requirements; risks related to the Company's ability to maintain and benefit from accelerated FDA review designations,

including BTD and RMAT, which may not ultimately result in a faster development process or review of the Company's product

candidates (and which may later be rescinded by the FDA if such product candidates no longer meet the conditions for qualification

for the program), and does not in any way assure approval of such product candidates by the FDA or the ability of the Company

to obtain FDA approval in time to benefit from commercial opportunities; and the ability of the Company to manufacture its therapies

using third party manufacturers. A further list and description of the Company's risks, uncertainties and other factors

can be found in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the Securities

and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking

statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such

forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contacts:

Media Relations Contact: